Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of modified FOLFIRINOX in metastatic neuroendocrine carcinoma
KCT0009337Phase 2Recruiting
- Sponsor
- Boryung
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, folinic acid, irinotecan and fluorouracil in neuroendocrine carcinoma (NEC), sponsored by Boryung. Primary endpoint: Tumor evaluation including disease progression by RECIST 1.1. Started Dec 2024; status: recruiting.
02
Drugs
oxaliplatinfolinic acidirinotecanfluorouracil
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on KCT0009337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009337.